Toca 511 & Toca FC: Evaluation of Durable Response Rate in the Post-Resection Setting and Association with Survival in Patients with Recurrent High Grade Glioma

被引：0

作者：

Cloughesy, Timothy ^{[1
]}

Landolfi, Joseph ^{[2
]}

Vogelbaum, Michael ^{[3
]}

Ostertag, Derek ^{[4
]}

Elder, Bradley ^{[5
]}

Carter, Bob ^{[6
]}

Chen, Clark ^{[7
]}

Kalkanis, Steven ^{[8
]}

Kesari, Santosh ^{[9
]}

Lai, Albert ^{[1
]}

Lee, Ian ^{[8
]}

Liau, Linda ^{[1
]}

Nghiemphu, Phioanh ^{[1
]}

Piccioni, David ^{[10
]}

Accomando, William ^{[4
]}

Diago, Oscar ^{[4
]}

Hogan, Daniel ^{[4
]}

Jolly, Douglas ^{[4
]}

Wood, Katie ^{[4
]}

Kheoh, Thian ^{[4
]}

Gruber, Harry ^{[4
]}

Das, Asha ^{[4
]}

Walbert, Tobias ^{[8
]}

机构：

[1] Univ Calif Los Angeles, Los Angeles, CA USA

[2] New Jersey Neurosci Inst, Edison, NJ USA

[3] Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA

[4] Tocagen Inc, San Diego, CA USA

[5] Ohio State Univ, Columbus, OH 43210 USA

[6] MGH, Boston, MA USA

[7] Univ Minnesota, Minneapolis, MN USA

[8] Henry Ford Hosp, Detroit, MI 48202 USA

[9] John Wayne Canc Inst, Santa Monica, CA USA

[10] UCSD, San Diego, CA USA

来源：

NEUROLOGY | 2018年 / 90卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

S23.006

引用

页数：4

共 42 条

[21] Long-term follow-up data from 123 patients with recurrent high grade glioma from three Phase 1 trials of Toca 511 and Toca FC: Update and justification for a Phase 2/3 trial
Huang, Tiffany T.
Aghi, Manish
Vogelbaum, Michael
Kalkanis, Steven
Bota, Daniela
Carter, Bob
Chen, Clark
Elder, Bradley
Kaptain, George
Kesari, Santosh
Cloughesy, Timothy
Walbert, Tobias
JOURNAL OF NEUROSURGERY, 2017, 126 (04) : A1414 - A1414
[22] Interim Report from Two Ongoing Ascending Dose Trials of a Retroviral Replicating Vector (Toca 511) in Patients with Recurrent High Grade Glioma
Jolly, Douglas J.
Ibanez, Carlos
Robbins, Joan M.
Ostertag, Derek
Kasahara, Noriyuki
Aghi, Manish K.
Vogelbaum, Michael A.
Bankiewicz, Krystof
Cloughsey, Timothy F.
Liau, Linda M.
Chang, Susan M.
Butowski, Nicholas
Kesari, Santosh
Chen, Clark
Mikkelsen, Tom
Kalkanis, Steven N.
Landolfi, Joseph C.
Bloomfield, Stephen M.
Elder, J. Bradley
Gruber, Harry E.
Pertschuk, Daniel
MOLECULAR THERAPY, 2014, 22 : S11 - S11
[23] INTRAVENOUS DELIVERY OF TOCA 511 IN PATIENTS WITH HIGH GRADE GLIOMA RESULTS IN QUANTIFIABLE EXPRESSION OF CYTOSINE DEAMINASE IN TUMOR TISSUE
Walbert, Tobias
Bota, Daniela
Vogelbaum, Michael
Kalkanis, Steven
Liau, Linda
Mikkelsen, Tom
Gruber, Harry
Shorr, Jolene
Rodriguez-Aquirre, Maria
Ostertag, Derek
Mitchell, Leah
Jolly, Douglas
Cloughesy, Timothy
NEURO-ONCOLOGY, 2017, 19 : 30 - 31
[24] Ascending dose trials of the safety and tolerability of Toca 511, a retroviral replicating vector encoding cytosine deaminase, in patients with recurrent high-grade glioma.
Pertschuk, Daniel
Cloughesy, Timothy Francis
Chang, Susan Marina
Aghi, Manish K.
Vogelbaum, Michael A.
Liau, Linda M.
Shafa, Bob B.
Yong, William H.
Chen, Clark
Kesari, Santosh
Ibanez, Carlos E.
Perez, Omar D.
Robbins, Joan M.
Jolly, Douglas J.
Gruber, Harry E.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[25] THE TOCA 7 STUDY: PHASE 1B STUDY OF TOCA 511, A LIVE GAMMA RETROVIRUS, AND TOCA FC, AN EXTENDED-RELEASE FORMULATION OF 5-FLUOROCYTOSINE COMBINED WITH STANDARD OF CARE IN NEWLY DIAGNOSED HIGH GRADE GLIOMA (NCT02598011)
Vogelbaum, Michael
Lassman, Andrew
Lee, Ian
Liau, Linda
Sonabend, Adam
Walbert, Tobias
Yang, Liqiang
Das, Asha
Cloughesy, Timothy
NEURO-ONCOLOGY, 2016, 18 : 2 - 2
[26] Ascending Dose Trials of a Retroviral Replicating Vector (Toca 511) in Patients with Recurrent High-Grade Glioma: Clinical Update, Molecular Analyses, and Proposed Mechanism of Action
Jolly, Douglas J.
Robbins, Joan M.
Ostertag, Derek
Ibanez, Carlos
Kasahara, Noriyuki
Gruber, Harry
Kalkanis, Steven N.
Vogelbaum, Michael
Aghi, Manish K.
Cloughesy, Timothy
Chu, Alice
Das, Asha
Skillings, Jamey
MOLECULAR THERAPY, 2016, 24 : S27 - S27
[27] A RT-qPCR Diagnostic System to Monitor Toca 511, a Cancer-selective Gene Therapy for the Treatment of Patients with Recurrent High-grade Glioma.
Sudin, Erik
Wang, Zuguang
Wang, Aprilgate
Weitz, Sara
Sidhu, Harwinder
Shields, Aileen
Chen, Joseph
Shields, Malcolm
Ostertag, Derek
Uzgiris, Arejas James
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[28] "Tag Team" Glioblastoma Therapy: Results From a Phase 1 Trial of Toca 511 and 5-Fluorocytosine for Recurrent High-Grade Glioma
Strebe, Joslyn K.
Lubin, Jonathan A.
Kuo, John S.
NEUROSURGERY, 2016, 79 (06) : N18 - N20
[29] Clinical update, molecular analyses, and proposed mechanism of action of Toca 511 a retroviral replicating vector in three ascending dose trials in patients with recurrent high-grade glioma
Jolly, D. J.
Ostertag, D.
Hogan, D.
Ibanez, C.
Mitchell, L.
Yagiz, K.
Kasahara, N.
Gruber, H.
Kalkanis, S. N.
Vogelbaum, M.
Aghi, M. K.
Cloughesy, T.
Das, A.
HUMAN GENE THERAPY, 2016, 27 (11) : A41 - A41
[30] INTRATUMORAL DELIVERY OF THE RETROVIRAL REPLICATING VECTOR (RRV) TOCA 511 IN SUBJECTS WITH RECURRENT HIGH GRADE GLIOMA: INTERIM REPORT OF PHASE 1 STUDY (NCT 01156584)
Aghi, Manish
Vogelbaum, Michael A.
Kesari, Santosh
Chen, Clark C.
Liau, Linda M.
Piccioni, David
Portnow, Jana
Chang, Susan
Robbins, Joan M.
Boyce, Tammy
Huang, Tiffany T.
Pertschuk, Dan
Ostertag, Derek
Cloughesy, Timothy F.
NEURO-ONCOLOGY, 2014, 16

← 1 2 3 4 5 →